Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | MC3R | P41968 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847912 | 1.00 | BCAT2 (0.58) | BCAT2L3MBTL1CYP2C19AOC3LMNA | |
| SCHEMBL10451774 | 0.84 | BCAT2 (0.51) | BCAT2L3MBTL1CYP2C19AOC3LMNA | |
| SCHEMBL1383474 | 0.82 | CYP2C19 (0.67) | BCAT2CYP2C19LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL904490 | 0.82 | GABBR2 (0.55) | BCAT2L3MBTL1CYP2C19AOC3LMNA | |
| SCHEMBL186610 | 0.82 | GABBR2 (0.55) | BCAT2L3MBTL1CYP2C19AOC3LMNA | |
| SCHEMBL9061130 | 0.82 | LMNA (0.54) | BCAT2L3MBTL1AOC3LMNASMN1; SMN2 | |
| SCHEMBL904476 | 0.82 | GABBR2 (0.55) | BCAT2L3MBTL1CYP2C19AOC3LMNA | |
| SCHEMBL3443640 | 0.81 | TAAR1 (0.57) | BCAT2L3MBTL1CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL3442990 | 0.80 | L3MBTL1 (0.64) | BCAT2L3MBTL1CYP2C19CYP2D6SLC6A3 | |
| Hydrochloric Acid SCHEMBL1373206 | 0.80 | GABBR2 (0.53) | BCAT2L3MBTL1CYP2C19AOC3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483277-B1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-9175009-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-04-02 | — | — | US | disclosed |
| US-8952043-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2784078-A1 | Benzoxepin pi3k inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8673952-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2013-01-10 | — | — | US | disclosed |
| US-8263633-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2483277-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R2 | BCAT2 1965/4885L3MBTL1 3812/4885CYP2C19 525/4885 |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | BCAT2 2971/4885L3MBTL1 3881/4885CYP2C19 1599/4885 |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | BCAT2 2971/4885L3MBTL1 3881/4885CYP2C19 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.